Strong RSV Vaccine Data Lifts Hopes After Years of Futility

Pfizer announced Tuesday that a large international study found vaccinating moms-to-be was nearly 82% effective at preventing severe cases of RSV in their babies’ most vulnerable first 90 days of life. At age 6 months, the vaccine still was proving 69% effective against serious illness.

Related Keywords

Texas ,United States ,Barney Graham ,Wilbur Chen ,William Schaffner ,Kena Swanson ,Jason Mclellan ,Centers For Disease ,Pfizer ,University Of Texas At Austin ,University Of Maryland School Medicine ,National Institutes Of Health ,Drug Administration ,Vanderbilt University ,Disease Control ,Respiratory Syncytial Virus ,National Institutes ,Maryland School ,Vaccines ,Health Care ,